轉甲狀腺素類澱粉沉積症變性治療市場－全球產業規模、佔有率、趨勢、機會與預測：按類型、治療方法、疾病類型、分銷管道、地區和競爭格局分類，2021-2031年

全球轉甲狀腺素類澱粉沉積症治療市場預計將從 2025 年的 77.8 億美元大幅成長至 2031 年的 178.2 億美元，複合年成長率達 14.81%。

該領域包括旨在穩定轉甲狀腺素蛋白或抑制其在肝臟中生成的藥物治療，從而防止澱粉樣蛋白原纖維在心臟和神經組織中積聚。全球人口老化和非侵入性核子醫學閃爍顯像的廣泛應用是推動該領域發展的主要因素，後者顯著提高了診斷準確性，優於傳統的切片檢查技術。例如，歐洲心臟學會報告稱，到2025年，約19%的病因不明的肥厚型心肌病老年患者將被診斷為轉甲狀腺素蛋白澱粉樣變性心肌病，這表明標靶篩檢正在發現更多患者。

然而，疾病修正治療的高成本構成了一大障礙，造成了嚴重的報銷難題，並限制了預算緊張的醫療體系獲得治療的機會。這些經濟限制導致治療啟動經常被延誤，甚至直接被拒付，即使全球確診病例數量持續成長，也有效地限制了收入成長。

市場促進因素

全球轉甲狀腺素類澱粉沉積症治療市場成長的關鍵促進因素是創新疾病修正治療的引入和日益廣泛的應用。醫療專業人員擴大使用標靶治療穩定轉甲狀腺素蛋白四聚體或抑制其在肝臟中的合成，從而改變疾病的自然進程。現有標準療法的強勁商業性表現和新產品的快速普及都反映了這一趨勢。例如，輝瑞在2024年第三季財報中宣布，其Vyndaqel產品系列的全球銷售額達到14.5億美元，在強勁需求的推動下實現了63%的營業成長。此外，Astra Zeneca在其2024年11月發布的2024年全年及第三季財報中宣布，其新推出的治療藥物Wainua的季度銷售額達到2300萬美元，表明該藥物在神經病變領域獲得了良好的早期應用。

強大的臨床研發管線和不斷增加的研發投入進一步鞏固了這一商業性勢頭，這些投入旨在拓展適應症並提高生存率。製藥公司正積極開發新一代RNA干擾和反義寡核苷酸療法，以治療傳統上難以治療的心肌病病變患者族群。基因沉默劑治療心臟疾病的療效已被證實，相關數據已取得顯著進展。 Alnylam Pharmaceuticals公司於2024年6月公佈的HELIOS-B III期臨床試驗結果顯示，在ATTR類澱粉沉積症合併心肌病病變患者中，butrisiran可顯著降低全因死亡率和復發性心血管事件的綜合風險達28%。這些進展對於獲得監管部門核准至關重要，預計這將在不久的將來顯著擴大市場規模。

市場挑戰

轉甲狀腺素類澱粉沉積症樣疾病修正治療的高昂費用是市場擴張的主要障礙，阻礙了診斷能力提升與產生收入之間的關聯。儘管篩檢計畫能夠識別出更多患者，但這些終身治療的高昂價格迫使公共和私人支付方實施嚴格的報銷通訊協定。這些經濟障礙體現在複雜的預先核准程序和拒付上，導致越來越多的確診患者無法獲得治療。因此，製造商面臨日益成長的臨床需求，但經濟障礙卻人為地限制了產品的實際應用。

這種經濟差距直接影響患者獲得治療的機會。根據類澱粉沉積症研究聯盟（ARCC）2024年的數據，五分之一的轉甲狀腺素類澱粉沉積症樣變性患者表示，由於費用或保險覆蓋問題，他們不得不推遲治療。由於相當一部分患者被迫推遲或中斷治療，經濟問題直接縮小了潛在市場規模，並阻礙了該領域的商業性發展。

市場趨勢

體內CRISPR-Cas9基因編輯療法的進展正在從根本上改變市場格局，將治療模式從慢性管理轉變為可能單次給藥根治性的方案。與目前需要持續給藥的基因沉默劑不同，這些新一代藥物利用脂質奈米顆粒永久地惰性肝細胞中的TTR基因，有效阻止致病蛋白的產生。近期公佈的持久性數據支持了單次給藥即可阻止疾病進展的潛力。例如，Intellia Therapeutics公司於2024年11月公佈了臨床實驗藥物Nexigran Dicurmeran的I期臨床試驗數據，結果顯示，無論基準水平如何，該藥物在12個月時均能顯著且持續地降低所有患者的平均血清TTR水平達90%。

同時，新一代高親和性TTR穩定劑的商業化正在樹立新的療效標準​​，與以往的療法相比，其四聚體穩定作用接近完全。這些新型小分子化合物旨在最大限度地提高循環結合率，並顯著減少導致心臟澱粉樣蛋白沉積的毒性單體的釋放。近期監管部門的核准也支持了這種向卓越穩定性發展的趨勢。根據BridgeBio Pharma公司2024年11月發布的關於Attruvy獲得FDA核准的公告，關鍵性3期ATTRibute-CM試驗的數據顯示，與安慰劑相比，Acoramidis在30個月時使全因死亡率和心血管相關再入院的綜合風險降低了42%。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球轉甲狀腺素類澱粉沉積症變性治療市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 按類型（ATTR-PN、ATTR-CM）
  • 治療方法（標靶治療（Onpattro、inotersen、Vyndaqel/Vindamax）、支持治療和研究治療方法）
  • 依疾病類型（遺傳性轉甲狀腺素類澱粉沉積症（神經病變、心肌病、混合型）、野生型類澱粉沉積症）
  • 按分銷管道（醫院藥房、專科藥房、零售藥房、網路藥房）
  • 按地區
  • 按公司（2025 年）
• 市場地圖

6. 北美轉甲狀腺素類澱粉沉積症治療市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國家分析
  • 美國
  • 加拿大
  • 墨西哥

7. 歐洲轉甲狀腺素類澱粉沉積症治療市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國家分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

8. 亞太地區轉甲狀腺素類澱粉沉積症治療市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國家分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

9. 中東和非洲轉甲狀腺素類澱粉沉積症樣變性治療市場展望

• 市場規模及預測
• 市佔率及預測
• 中東和非洲：國家分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

10. 南美洲轉甲狀腺素類澱粉沉積症治療市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國家分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進要素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 最新進展

第13章 全球轉甲狀腺素類澱粉沉積症治療市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的可能性
• 供應商電力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• Alnylam Pharmaceuticals
• Bridgebio Pharma
• Pfizer
• Ionis Pharmaceuticals
• Astrazeneca
• Alexion Pharmaceutical
• Proliferan
• Enobio Pharma
• Moderna
• Intellia Therapeutics
• Regeneron Pharmaceuticals

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global Transthyretin Amyloidosis Treatment Market is projected to expand significantly, rising from USD 7.78 Billion in 2025 to USD 17.82 Billion by 2031, reflecting a compound annual growth rate of 14.81%. This sector includes pharmacological treatments aimed at stabilizing the transthyretin protein or inhibiting its production in the liver to stop amyloid fibrils from accumulating in the heart and nerves. Growth is largely fueled by an aging global population and the widespread use of non-invasive nuclear scintigraphy, which has vastly improved diagnostic accuracy over older biopsy techniques. For instance, the European Society of Cardiology noted in 2025 that approximately 19% of elderly patients with unexplained hypertrophic cardiomyopathy were diagnosed with transthyretin amyloid cardiomyopathy, highlighting how targeted screening is revealing a larger patient base.

However, the market faces a major impediment due to the high costs associated with disease-modifying therapies, which create significant reimbursement obstacles and limit access within budget-constrained healthcare systems. These financial limitations frequently lead to delays in starting treatment or outright denial of insurance coverage, effectively curbing revenue growth even as the number of diagnosed cases continues to rise worldwide.

Market Driver

The primary engine for growth in the Global Transthyretin Amyloidosis Treatment Market is the introduction and increasing utilization of innovative disease-modifying therapies. Medical professionals are more frequently prescribing targeted treatments that either stabilize the transthyretin tetramer or suppress its hepatic synthesis, thereby modifying the disease's natural progression. This trend is highlighted by the strong commercial performance of existing standards of care and the rapid uptake of new products. For example, Pfizer Inc. reported in its Third Quarter 2024 Earnings that the Vyndaqel product family reached global revenues of USD 1.45 billion, representing 63 percent operational growth due to high demand. Additionally, AstraZeneca's Year to date and Q3 2024 Results in November 2024 indicated that its newly launched Wainua treatment generated USD 23 million in quarterly revenue, showing strong initial adoption in the polyneuropathy sector.

This commercial momentum is bolstered by a strong clinical pipeline and increased research and development investment aimed at broadening labeled indications and enhancing survival rates. Pharmaceutical companies are actively developing next-generation RNA interference and antisense oligonucleotide therapies to treat the larger cardiomyopathy patient group, which has historically been challenging to manage. A significant breakthrough occurred with the release of data confirming the effectiveness of gene silencers for cardiac issues; according to Alnylam Pharmaceuticals' June 2024 HELIOS-B Phase 3 Study Results, vutrisiran showed a statistically significant 28 percent reduction in the composite risk of all-cause mortality and recurrent cardiovascular events in patients with ATTR amyloidosis and cardiomyopathy. These advancements are essential for regulatory approvals that are expected to substantially expand the market size in the near future.

Market Challenge

A major barrier to market expansion is the exorbitant cost of disease-modifying therapies for transthyretin amyloidosis, which disrupts the link between improved diagnostic capabilities and revenue generation. Although screening programs are successfully identifying more patients, the steep prices of these lifelong medications force public and private insurers to implement strict reimbursement protocols. These financial hurdles often appear as complicated prior authorization processes or coverage refusals, preventing the growing pool of diagnosed patients from accessing treatment. As a result, manufacturers encounter a situation where clinical demand is increasing, yet actual product adoption is artificially constrained by economic gatekeeping.

The disconnect caused by financial toxicity directly affects patient access to care. Data from the Amyloidosis Research Consortium in 2024 revealed that one in five patients with transthyretin amyloidosis reported delaying treatment initiation specifically because of costs or insurance coverage difficulties. With a significant segment of the patient population compelled to postpone or forego therapy, affordability issues are directly shrinking the practical market size and hindering the sector's commercial trajectory.

Market Trends

The market is being fundamentally transformed by the advancement of In Vivo CRISPR-Cas9 gene editing therapeutics, which are shifting the treatment paradigm from chronic management to potential one-time curative solutions. Unlike current gene silencers that require ongoing administration, these next-generation agents use lipid nanoparticles to permanently disable the TTR gene in hepatocytes, effectively stopping the production of disease-causing proteins. The potential for a single dose to halt disease progression is supported by recent durability data; for instance, Intellia Therapeutics announced in its November 2024 Phase 1 Clinical Data that the investigational agent nexiguran ziclumeran achieved a deep and consistent mean serum TTR reduction of 90 percent at month 12 across all patients, irrespective of baseline levels.

Concurrently, the commercialization of next-generation high-affinity TTR stabilizers is setting a new benchmark for efficacy by achieving near-complete tetramer stabilization compared to earlier options. These novel small molecules are designed to maximize blood binding occupancy, thereby significantly lowering the release of toxic monomers responsible for amyloid deposition in the heart. This evolution toward superior stabilization was confirmed by recent regulatory achievements; according to BridgeBio Pharma's November 2024 announcement regarding the FDA approval for Attruby, data from the pivotal Phase 3 ATTRibute-CM trial demonstrated that acoramidis resulted in a 42 percent reduction in the composite risk of all-cause mortality and recurrent cardiovascular-related hospitalizations at month 30 compared to placebo.

Key Market Players

• Alnylam Pharmaceuticals
• Bridgebio Pharma
• Pfizer
• Ionis Pharmaceuticals
• Astrazeneca
• Alexion Pharmaceutical
• Proliferan
• Enobio Pharma
• Moderna
• Intellia Therapeutics
• Regeneron Pharmaceuticals

Report Scope

In this report, the Global Transthyretin Amyloidosis Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Transthyretin Amyloidosis Treatment Market, By Type

• ATTR-PN
• ATTR-CM

Transthyretin Amyloidosis Treatment Market, By Therapy

• Targeted Therapy (Onpattro, Inotersen, Vyndaqel/Vyndamax)
• Supportive Therapy
• Pipeline Therapy

Transthyretin Amyloidosis Treatment Market, By Disease Type

• Hereditary Transthyretin Amyloidosis (Polyneuropathy, Cardiomyopathy, Mixed Type)
• Wild Type Amyloidosis

Transthyretin Amyloidosis Treatment Market, By Distribution Channel

• Hospital Pharmacies
• Specialty Pharmacies
• Retail Pharmacies
• Online Pharmacies

Transthyretin Amyloidosis Treatment Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Transthyretin Amyloidosis Treatment Market.

Available Customizations:

Global Transthyretin Amyloidosis Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Transthyretin Amyloidosis Treatment Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (ATTR-PN, ATTR-CM)
  • 5.2.2. By Therapy (Targeted Therapy (Onpattro, Inotersen, Vyndaqel/Vyndamax), Supportive Therapy, Pipeline Therapy)
  • 5.2.3. By Disease Type (Hereditary Transthyretin Amyloidosis (Polyneuropathy, Cardiomyopathy, Mixed Type), Wild Type Amyloidosis)
  • 5.2.4. By Distribution Channel (Hospital Pharmacies, Specialty Pharmacies, Retail Pharmacies, Online Pharmacies)
  • 5.2.5. By Region
  • 5.2.6. By Company (2025)
• 5.3. Market Map

6. North America Transthyretin Amyloidosis Treatment Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Therapy
  • 6.2.3. By Disease Type
  • 6.2.4. By Distribution Channel
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Transthyretin Amyloidosis Treatment Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Therapy
      • 6.3.1.2.3. By Disease Type
      • 6.3.1.2.4. By Distribution Channel
  • 6.3.2. Canada Transthyretin Amyloidosis Treatment Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Therapy
      • 6.3.2.2.3. By Disease Type
      • 6.3.2.2.4. By Distribution Channel
  • 6.3.3. Mexico Transthyretin Amyloidosis Treatment Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Therapy
      • 6.3.3.2.3. By Disease Type
      • 6.3.3.2.4. By Distribution Channel

7. Europe Transthyretin Amyloidosis Treatment Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Therapy
  • 7.2.3. By Disease Type
  • 7.2.4. By Distribution Channel
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Transthyretin Amyloidosis Treatment Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Therapy
      • 7.3.1.2.3. By Disease Type
      • 7.3.1.2.4. By Distribution Channel
  • 7.3.2. France Transthyretin Amyloidosis Treatment Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Therapy
      • 7.3.2.2.3. By Disease Type
      • 7.3.2.2.4. By Distribution Channel
  • 7.3.3. United Kingdom Transthyretin Amyloidosis Treatment Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Therapy
      • 7.3.3.2.3. By Disease Type
      • 7.3.3.2.4. By Distribution Channel
  • 7.3.4. Italy Transthyretin Amyloidosis Treatment Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Therapy
      • 7.3.4.2.3. By Disease Type
      • 7.3.4.2.4. By Distribution Channel
  • 7.3.5. Spain Transthyretin Amyloidosis Treatment Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Therapy
      • 7.3.5.2.3. By Disease Type
      • 7.3.5.2.4. By Distribution Channel

8. Asia Pacific Transthyretin Amyloidosis Treatment Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Therapy
  • 8.2.3. By Disease Type
  • 8.2.4. By Distribution Channel
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Transthyretin Amyloidosis Treatment Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Therapy
      • 8.3.1.2.3. By Disease Type
      • 8.3.1.2.4. By Distribution Channel
  • 8.3.2. India Transthyretin Amyloidosis Treatment Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Therapy
      • 8.3.2.2.3. By Disease Type
      • 8.3.2.2.4. By Distribution Channel
  • 8.3.3. Japan Transthyretin Amyloidosis Treatment Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Therapy
      • 8.3.3.2.3. By Disease Type
      • 8.3.3.2.4. By Distribution Channel
  • 8.3.4. South Korea Transthyretin Amyloidosis Treatment Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Therapy
      • 8.3.4.2.3. By Disease Type
      • 8.3.4.2.4. By Distribution Channel
  • 8.3.5. Australia Transthyretin Amyloidosis Treatment Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Therapy
      • 8.3.5.2.3. By Disease Type
      • 8.3.5.2.4. By Distribution Channel

9. Middle East & Africa Transthyretin Amyloidosis Treatment Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Therapy
  • 9.2.3. By Disease Type
  • 9.2.4. By Distribution Channel
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Transthyretin Amyloidosis Treatment Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Therapy
      • 9.3.1.2.3. By Disease Type
      • 9.3.1.2.4. By Distribution Channel
  • 9.3.2. UAE Transthyretin Amyloidosis Treatment Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Therapy
      • 9.3.2.2.3. By Disease Type
      • 9.3.2.2.4. By Distribution Channel
  • 9.3.3. South Africa Transthyretin Amyloidosis Treatment Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Therapy
      • 9.3.3.2.3. By Disease Type
      • 9.3.3.2.4. By Distribution Channel

10. South America Transthyretin Amyloidosis Treatment Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Therapy
  • 10.2.3. By Disease Type
  • 10.2.4. By Distribution Channel
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Transthyretin Amyloidosis Treatment Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Therapy
      • 10.3.1.2.3. By Disease Type
      • 10.3.1.2.4. By Distribution Channel
  • 10.3.2. Colombia Transthyretin Amyloidosis Treatment Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Therapy
      • 10.3.2.2.3. By Disease Type
      • 10.3.2.2.4. By Distribution Channel
  • 10.3.3. Argentina Transthyretin Amyloidosis Treatment Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Therapy
      • 10.3.3.2.3. By Disease Type
      • 10.3.3.2.4. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Transthyretin Amyloidosis Treatment Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Alnylam Pharmaceuticals
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Bridgebio Pharma
• 15.3. Pfizer
• 15.4. Ionis Pharmaceuticals
• 15.5. Astrazeneca
• 15.6. Alexion Pharmaceutical
• 15.7. Proliferan
• 15.8. Enobio Pharma
• 15.9. Moderna
• 15.10. Intellia Therapeutics
• 15.11. Regeneron Pharmaceuticals

16. Strategic Recommendations

17. About Us & Disclaimer